Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-26 @ 11:10 AM
Ignite Modification Date:
2025-12-26 @ 11:10 AM
NCT ID:
NCT05799612
Brief Summary:
To find the highest tolerable dose of an mRNA vaccine that can be safely given to patients with cutaneous angiosarcoma
Detailed Description:
Objectives:
Primary objective:
•To determine the safety, toxicity, and feasibility of delivering autologous dendritic cells (DCs) loaded with tumor lysate plus mRNA to patients with cutaneous head \& neck angiosarcoma as adjuvant therapy.
Secondary objective:
• To assess the recurrence free survival and overall survival in treated patients in order to make initial assessment of activity of this therapeutic approach
Exploratory Objectives:
• To quantitate immune responses in patients who receive autologous DCs loaded with tumor lysate plus mRNA
Study:
NCT05799612
Study Brief:
Protocol Section:
NCT05799612